CA3247772A1 - Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their uses - Google Patents
Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their usesInfo
- Publication number
- CA3247772A1 CA3247772A1 CA3247772A CA3247772A CA3247772A1 CA 3247772 A1 CA3247772 A1 CA 3247772A1 CA 3247772 A CA3247772 A CA 3247772A CA 3247772 A CA3247772 A CA 3247772A CA 3247772 A1 CA3247772 A1 CA 3247772A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- pharmaceutically acceptable
- acceptable salt
- syndrome
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302246P | 2022-01-24 | 2022-01-24 | |
| US63/302,246 | 2022-01-24 | ||
| PCT/IB2023/050504 WO2023139534A1 (en) | 2022-01-24 | 2023-01-20 | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3247772A1 true CA3247772A1 (en) | 2023-07-27 |
Family
ID=85150566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3247772A Pending CA3247772A1 (en) | 2022-01-24 | 2023-01-20 | Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their uses |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250115572A1 (https=) |
| EP (1) | EP4469157A1 (https=) |
| JP (1) | JP2025504859A (https=) |
| KR (1) | KR20240138095A (https=) |
| CN (1) | CN118696035A (https=) |
| AU (1) | AU2023209631A1 (https=) |
| CA (1) | CA3247772A1 (https=) |
| CL (1) | CL2024002205A1 (https=) |
| CO (1) | CO2024009660A2 (https=) |
| CR (1) | CR20240300A (https=) |
| DO (1) | DOP2024000142A (https=) |
| IL (1) | IL314186A (https=) |
| JO (1) | JOP20240165A1 (https=) |
| MX (1) | MX2024009062A (https=) |
| PE (1) | PE20242005A1 (https=) |
| WO (1) | WO2023139534A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202334121A (zh) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | 哌啶基吲哚衍生物、其製備方法及醫藥用途 |
| TW202423426A (zh) * | 2022-08-31 | 2024-06-16 | 美商奇努克醫療股份有限公司 | 經取代之吲哚化合物及其使用方法 |
| IL320661A (en) * | 2022-11-14 | 2025-07-01 | Novartis Pharma Ag | Solid forms of complement factor B inhibitors |
| TW202506657A (zh) * | 2023-04-27 | 2025-02-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種哌啶基吲哚化合物的鹽及其製備方法 |
| CN121889385A (zh) | 2023-07-04 | 2026-04-17 | 希塔拉生物有限公司 | 作为因子b抑制剂的2-(1h-吲哚-4-基)甲基)2h-吲唑衍生物 |
| IL325760A (en) | 2023-07-04 | 2026-03-01 | Sitala Bio Ltd | History of 2-(1H-indol-4-yl)methyl)-isoindoline as factor B inhibitors |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| AU2024324780A1 (en) * | 2023-08-16 | 2026-02-05 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| TW202543599A (zh) * | 2024-03-08 | 2025-11-16 | 大陸商江蘇豪森藥業集團有限公司 | 一種多元螺環化合物的晶型、其製備方法和醫藥用途 |
| WO2025256600A1 (zh) * | 2024-06-12 | 2025-12-18 | 润尔眼科药物（广州）有限公司 | 一种杂环化合物及其用途 |
| WO2026002007A1 (zh) * | 2024-06-25 | 2026-01-02 | 珠海联邦制药股份有限公司 | 补体因子b抑制剂及其药物组合物和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| RS66635B1 (sr) * | 2017-08-31 | 2025-04-30 | Novartis Ag | Derivati piperidinil-indola za upotrebu u lečenju c3 glomerulopatije |
| KR20230049115A (ko) * | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| CN120081822A (zh) * | 2021-06-03 | 2025-06-03 | 诺瓦提斯药物公司 | 经取代的吲哚化合物及其使用方法 |
| EP4389742A4 (en) * | 2021-08-18 | 2026-01-14 | Xizang Haisco Pharmaceutical Co Ltd | HETEROAROMATIC CYCLE DERIVATIVE CONTAINING BENZO NITROGEN AND ITS USE IN MEDICINE |
| TW202334121A (zh) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | 哌啶基吲哚衍生物、其製備方法及醫藥用途 |
-
2023
- 2023-01-20 CA CA3247772A patent/CA3247772A1/en active Pending
- 2023-01-20 CR CR20240300A patent/CR20240300A/es unknown
- 2023-01-20 JP JP2024543097A patent/JP2025504859A/ja active Pending
- 2023-01-20 CN CN202380019453.6A patent/CN118696035A/zh active Pending
- 2023-01-20 PE PE2024001666A patent/PE20242005A1/es unknown
- 2023-01-20 AU AU2023209631A patent/AU2023209631A1/en active Pending
- 2023-01-20 EP EP23702675.2A patent/EP4469157A1/en active Pending
- 2023-01-20 WO PCT/IB2023/050504 patent/WO2023139534A1/en not_active Ceased
- 2023-01-20 IL IL314186A patent/IL314186A/en unknown
- 2023-01-20 MX MX2024009062A patent/MX2024009062A/es unknown
- 2023-01-20 US US18/729,949 patent/US20250115572A1/en active Pending
- 2023-01-20 KR KR1020247027601A patent/KR20240138095A/ko active Pending
-
2024
- 2024-07-22 CO CONC2024/0009660A patent/CO2024009660A2/es unknown
- 2024-07-22 CL CL2024002205A patent/CL2024002205A1/es unknown
- 2024-07-22 DO DO2024000142A patent/DOP2024000142A/es unknown
- 2024-07-24 JO JOJO/P/2024/0165A patent/JOP20240165A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025504859A (ja) | 2025-02-19 |
| WO2023139534A1 (en) | 2023-07-27 |
| CR20240300A (es) | 2024-08-23 |
| KR20240138095A (ko) | 2024-09-20 |
| IL314186A (en) | 2024-09-01 |
| MX2024009062A (es) | 2024-07-29 |
| CO2024009660A2 (es) | 2024-07-29 |
| AU2023209631A1 (en) | 2024-07-25 |
| CL2024002205A1 (es) | 2025-01-10 |
| DOP2024000142A (es) | 2024-08-30 |
| US20250115572A1 (en) | 2025-04-10 |
| PE20242005A1 (es) | 2024-10-03 |
| CN118696035A (zh) | 2024-09-24 |
| JOP20240165A1 (ar) | 2024-07-24 |
| EP4469157A1 (en) | 2024-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3247772A1 (en) | Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their uses | |
| WO2023187715A1 (en) | Complement factor b inhibitors and uses thereof | |
| CN105229003B (zh) | 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物 | |
| CN105579444B (zh) | 哌啶基吲哚衍生物和它们作为补体因子b抑制剂的用途 | |
| CN104619698B (zh) | 吡咯烷衍生物及其作为补体途径调节剂的用途 | |
| CN104603126B (zh) | 吡咯烷衍生物及其作为补体途径调节剂的用途 | |
| JP2024519496A (ja) | ブルトンのチロシンキナーゼの分解を標的化するための化合物 | |
| CN105939997A (zh) | 作为dlk抑制剂的吡唑衍生物及其用途 | |
| WO2025068951A1 (en) | Complement factor b inhibitors and uses thereof | |
| CN108699080B (zh) | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 | |
| JP2023502857A (ja) | Ｌｒｒｋ２阻害薬としてのｎ－（ヘテロアリール）キナゾリン－２－アミン誘導体、医薬組成物及びその使用 | |
| US8178552B2 (en) | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | |
| TW201726651A (zh) | ２，３，４，５－四氫吡啶－６－胺衍生物 | |
| TW202448456A (zh) | 作為對ｃ－ｃｂｌ具選擇性之ｃｂｌ－ｂ抑制劑的６－經取代－３－苯基－異吲哚啉－１－酮類 | |
| EP4536642A1 (en) | Heterocyclic compounds as pi3ka inhibitors | |
| HK40058692A (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| HK40085586B (zh) | 哒嗪基噻唑甲酰胺类化合物 | |
| HK40084227B (zh) | 哒嗪基噻唑甲醯胺类化合物 | |
| HK40059656B (zh) | 哒嗪基噻唑甲酰胺类化合物 | |
| HK1262295B (zh) | 6 ,7-二氢-5H-吡唑并[5 ,1-b][1 ,3]恶嗪-2-甲酰胺化合物 | |
| HK1262295A1 (en) | 6,7-dihydro-5h-pyrazolo[5，1-b][1,3]oxazine-2-carboxamide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240709 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241128 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241128 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241128 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241202 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241216 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241216 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251216 |